Literature DB >> 17388261

Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.

Khoon Lin Ling1, Sarah E Pratap, Gaynor J Bates, Baljit Singh, Neil J Mortensen, Bruce D George, Bryan F Warren, Juan Piris, Giovanna Roncador, Stephen B Fox, Alison H Banham, Vincenzo Cerundolo.   

Abstract

Recent results have shown a correlation between survival and frequency of tumour infiltrating T lymphocytes in colorectal cancer patients. However, it remains unclear whether the frequency of regulatory T cells is higher in colorectal cancer as compared to normal colon. To address this question we analysed the frequency and function of regulatory T cells in the peripheral blood and tumour infiltrating lymphocytes of colorectal cancer patients. The proportion of regulatory T cells in the peripheral blood of colorectal cancer patients (mean 8%) was significantly higher than that in normal controls (mean 2.2%). There were significantly more regulatory T cells in tumour infiltrating lymphocytes (mean 19.2%) compared to lymphocytes from an autologous non-malignant portion of the colon (mean 9%). Regulatory T cells from colorectal cancer patients were FOXP3 positive and suppressed the proliferation of autologous CD4+ CD25- cells. A higher density of tumour infiltrating regulatory T cells was found in patients with advanced as compared to early disease. These results support the hypothesis that increased numbers of regulatory T cells in the blood and tumours of colorectal cancer patients may influence the immune response against cancer and suggest that strategies to overcome regulatory T cell activity may be beneficial in the treatment of human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388261      PMCID: PMC2935744     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  31 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

2.  Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab.

Authors:  Ola Lindén
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

3.  Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients.

Authors:  Anna Lundgren; Erika Strömberg; Asa Sjöling; Catharina Lindholm; Karin Enarsson; Anders Edebo; Erik Johnsson; Elisabeth Suri-Payer; Pia Larsson; Anna Rudin; Ann-Mari Svennerholm; B Samuel Lundin
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

5.  Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery.

Authors:  N S Ambrose; M Johnson; D W Burdon; M R Keighley
Journal:  Br J Surg       Date:  1984-08       Impact factor: 6.939

6.  Increased tight junctional permeability is associated with the development of colon cancer.

Authors:  A P Soler; R D Miller; K V Laughlin; N Z Carp; D M Klurfeld; J M Mullin
Journal:  Carcinogenesis       Date:  1999-08       Impact factor: 4.944

7.  Bacterial translocation in colorectal cancers.

Authors:  D Lescut; J F Colombel; P Vincent; A Cortot; L Fournier; P Quandalle; M Vankemmel; J P Triboulet; A Wurtz; J C Paris
Journal:  Gastroenterol Clin Biol       Date:  1990

8.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

9.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.

Authors:  Y Chen; V K Kuchroo; J Inobe; D A Hafler; H L Weiner
Journal:  Science       Date:  1994-08-26       Impact factor: 47.728

10.  A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.

Authors:  H Groux; A O'Garra; M Bigler; M Rouleau; S Antonenko; J E de Vries; M G Roncarolo
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

View more
  62 in total

Review 1.  Immune profiling and cancer post transplantation.

Authors:  Christopher Martin Hope; Patrick Toby H Coates; Robert Peter Carroll
Journal:  World J Nephrol       Date:  2015-02-06

2.  T-cell responses to survivin in cancer patients undergoing radiation therapy.

Authors:  Dörthe Schaue; Begonya Comin-Anduix; Antoni Ribas; Li Zhang; Lee Goodglick; James W Sayre; Annelies Debucquoy; Karin Haustermans; William H McBride
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

Authors:  Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

Review 4.  Mesenchymal cells of the intestinal lamina propria.

Authors:  D W Powell; I V Pinchuk; J I Saada; Xin Chen; R C Mifflin
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

5.  Upregulation of Treg-Related Genes in Addition with IL6 Showed the Significant Role for the Distant Metastasis in Colorectal Cancer.

Authors:  L D Miteva; N S Stanilov; G М Cirovski; Spaska Angelova Stanilova
Journal:  Cancer Microenviron       Date:  2017-09-03

Review 6.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.

Authors:  Scott S Tykodi; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

7.  Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer.

Authors:  Nichole R Blatner; Mary F Mulcahy; Kristen L Dennis; Denise Scholtens; David J Bentrem; Joseph D Phillips; Soo Ham; Barry P Sandall; Mohammad W Khan; David M Mahvi; Amy L Halverson; Steven J Stryker; Anne-Marie Boller; Ashima Singal; Rebekka K Sneed; Bara Sarraj; Mohammed Javeed Ansari; Martin Oft; Yoichiro Iwakura; Liang Zhou; Andreas Bonertz; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie
Journal:  Sci Transl Med       Date:  2012-12-12       Impact factor: 17.956

8.  Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.

Authors:  Vanessa Deschoolmeester; Marc Baay; Eric Van Marck; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken
Journal:  BMC Immunol       Date:  2010-04-12       Impact factor: 3.615

9.  Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice.

Authors:  Jinlin Liu; Ning Zhang; Qun Li; Weiwei Zhang; Fang Ke; Qibin Leng; Hong Wang; Jinfei Chen; Honglin Wang
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 10.  Regulatory T cells in inflammatory bowel diseases and colorectal cancer.

Authors:  Györgyi Műzes; Béla Molnár; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.